SMARCA4-Directed Treatment in Oncology Clinical Trials: A Review

Division

Mountain

Hospital

Sky Ridge Medical Center

Document Type

Review Article

Publication Date

6-11-2026

Keywords

SMARCA4, cancer, clinical trials, review article

Disciplines

Internal Medicine | Medicine and Health Sciences | Neoplasms

Abstract

SMARCA4 is an ATPase subunit in the switch/sucrose non-fermentable complex (SWI/SNF), a chromatin-remodeling complex. SMARCA4 provides energy for the SWI/SNF complex to regulate gene expression through chromatin structural rearrangement and transcription regulation. In SMARCA4-deficient cancers, its paralog SMARCA2 is sometimes upregulated and can serve as a pharmacological target. Of the 20-25% of cancers identified to have a mutation in a gene encoding a protein for the SWI/SNF complex, 15% of these alterations include

Publisher or Conference

Journal of Immunotherapy and Precision Oncology

Link to Full Text

Share

COinS